[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576225":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":57,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Dose Group","ACTIVE_COMPARATOR","Patients with knee osteoarthritis who are interested in knee intra-articular corticosteroid injections and meet the inclusion criteria.",[13],"Drug: Triamcinolone Acetonide Standard Dose",{"label":15,"type":16,"description":11,"interventionNames":17},"Lower Dose Group","EXPERIMENTAL",[18],"Drug: Triamcinolone Acetonide Low Dose",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Triamcinolone Acetonide Low Dose","Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.\n\nTotal injection volume of 5ml, consisting of:\n\n* 0.5ml triamcinolone acetonide (20mg)\n* 4.5ml lidocaine (45mg)",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Triamcinolone Acetonide Standard Dose","Subjects will receive the standard of care dose of 40mg triamcinolone acetonide\n\nTotal injection volume of 5ml, consisting of:\n\n* 1ml triamcinolone acetonide (40mg)\n* 4ml lidocaine (40mg)",[9],[31],{"name":32,"affiliation":5,"role":33},"Jeffrey P Nadwodny, DO","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","904 953 6722","nadwodny.jeffrey@mayo.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Mayo Clinic in Florida","RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-81.65565,30.33218,{"lat":52,"lon":51},[55,56],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Jeff P. Nadwodny","Assistant Professor of Family Medicine","100576225","phase-4-knee-injections-for-obese-patients-with-knee-arthritis-100576225",false,"NCT06782529","Knee Injections for Obese Patients With Knee Arthritis","Comparison of Varying Doses of Steroid for Intra-articular Knee Injections","Inclusion Criteria:\n\n• Patients with BMI ≥30 kg\u002Fm2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis.\n\nExclusion Criteria:\n\n* BMI \\\u003C 30 kg\u002Fm2\n* Uncontrolled diabetics with a hemoglobin A1c \\> 8%\n* No other treatment within the time frame of the study.\n* Patients that are undergoing physical therapy at the time of the study.","ALL","55 Years","85 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.",[78],"Osteoarthritis of Knee",[80,81,82],"Knee Osteoarthritis","Corticosteroid Injection","Obesity","2026-03-06",{"date":85,"type":86},"2026-03-10","ACTUAL",{"date":88,"type":86},"2025-01-24",{"date":90,"type":72},"2027-01-24",{"name":5,"class":6},1]